Shlomi Raz, Eleusis CEO

Psy­che­delics biotech set to go pub­lic via SPAC — push­ing IV form of psilo­cy­bin in­to PhI

Psy­che­delics biotech Eleu­sis has its eyes on an ex­pan­sion, and it’s go­ing the SPAC route to get it.

The biotech an­nounced ear­li­er to­day that it’s team­ing up with a SPAC born out of as­set man­ag­er Sil­ver Spike Cap­i­tal to make Eleu­sis a pub­lic com­pa­ny. Once the deal goes through some­time in Q2 or Q3 this year, the com­bined com­pa­ny will be op­er­at­ed through new hold­ing com­pa­ny Eleu­sis Inc and trade on Nas­daq un­der the tick­er $ELEU.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.